Tropisetron for Postoperative Nausea and Vomiting in Patients After Gynaecological Surgery

Abstract

In a double-blind study, we have compared the prophylactic antiemetic effect of tropisetron 5 mg (Navoban, a 5-HT3 receptor antagonist) with that of placebo, both given as a short i.v. infusion approximately 15 min before wound closure in patients undergoing gynaecological surgery. Perioperative anaesthetic care was standardized and patients were observed for at least 24 h after operation. The 35 patients given tropisetron and 34 given placebo treatment were well matched for characteristics. Vomiting occurred in 26% of tropisetron-treated patients, compared with 59% of placebo-treated patients (P = 0.006); 69% of tropisetron-treated patients suffered nausea, compared with 88% of placebo-treated patients (P = 0.05). In addition, patients judged the antiemetic treatment with tropisetron as more effective than the placebo treatment (visual analogue score 71 vs 51 mm (P = 0.003)).

Prophylactic antiemetic therapy with ondansetron, tropisetron, granisetron and metoclopramide in patients undergoing laparoscopic cholecystectomy: a randomized, double-blind comparison with placebo

“…Our baseline incidence of PONV (72%) in the placebo group is consistent with the incidence reported in previous studies for patients who underwent other surgical procedures. 7,1~ Zomers et al 7 noted that nausea and vomiting occurred in 88% and 59%, respectively, in the placebo-treated patients. Similarly, Larijani et al 12 reported that 72% of their patient in the placebo group suffered from PONV.…”

“…In patients undergoing gynaecological surgery, Zomers et al 7 reported that vomiting occurred in 26% of tropisetron (5 mg)-treated patients compared with 59% of placebo-treated patients (P = 0.006). The incidence of nausea was, respectively, 69% and 88% (P = 0.05).…”

Prevention and Treatment of Postoperative Nausea and Vomiting

“…Tropisetron has an elimination half-life of 8-12 h [136] and has been studied for prevention [137][138][139] and treatment [140] of PONV in adults. Tropisetron has been found effective for prevention of PONV after breast [137] and gynecologic surgery [138] when a 5-mg IV dose was administered prior to the start of anesthesia [137,138].…”

“…Tropisetron has been found effective for prevention of PONV after breast [137] and gynecologic surgery [138] when a 5-mg IV dose was administered prior to the start of anesthesia [137,138]. Zomers et al [139] determined that tropisetron 5 mg was effective for prevention of PONV following gynecological surgery. Alon et al [140] determined that tropisetron 2 mg IV was the optimal effective dose for the treatment of PONV following a variety of abdominal and non-abdominal surgeries (table 5).…”

RETRACTED ARTICLE: Current prevention and treatment of postoperative nausea and vomiting with 5-hydroxytryptamine type 3 receptor antagonists: a review

“…Tropisetron (Table 3) In a randomized, double-blind, placebo-controlled study, the prophylactic antiemetic tropisetron, administered at a dose of 5 mg i.v., effectively reduced the incidence of PONV after gynecologic surgery [51,52]. Capouet et al [53] have compared the efficacy of tropisetron at three different doses (0.5, 2, and 5 mg) with the effect of placebo administered i.v.…”